38 related articles for article (PubMed ID: 2263237)
1. Adoptive immunotherapy of a mouse colon carcinoma with recombinant interleukin-2 alone or combined with lymphokine-activated killer cells or tumor-immune lymphocytes. Survival benefit of adjuvant post-surgical treatments and comparison with experimental metastases model.
Rodolfo M; Salvi C; Bassi C; Parmiani G
Cancer Immunol Immunother; 1990; 31(1):28-36. PubMed ID: 2306753
[TBL] [Abstract][Full Text] [Related]
2. Induction of antitumor activities in spleen cells from mice and rats activated with lipopolysaccharide immobilized on beads.
Abe H; Tani T; Shibata J; Kodama M
Cancer Immunol Immunother; 1992; 35(1):39-45. PubMed ID: 1611621
[TBL] [Abstract][Full Text] [Related]
3. Improved therapeutic effects of interleukin 2 after the accumulation of lymphokine-activated killer cells in tumor tissue of mice previously treated with cyclophosphamide.
Hosokawa M; Sawamura Y; Morikage T; Okada F; Xu ZY; Morikawa K; Itoh K; Kobayashi H
Cancer Immunol Immunother; 1988; 26(3):250-6. PubMed ID: 3260132
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of therapeutic effect of interleukin-2 on spontaneous pulmonary metastases of Lewis lung carcinoma by killer helper factor associated with increased induction of killer activity.
Fukuta K; Sone S; Kitahara M; Okada M; Ogura T
Jpn J Cancer Res; 1989 Jun; 80(6):562-7. PubMed ID: 2503476
[TBL] [Abstract][Full Text] [Related]
5. In vivo generation of lymphokine activated killer cell activity by ABPP and interleukin-2 and their antitumor effects against immunogenic and nonimmunogenic tumors in murine tumor models.
Eggermont AM; Sugarbaker PH; Marquet RL; Jeekel J
Cancer Immunol Immunother; 1988; 26(1):23-30. PubMed ID: 3257900
[TBL] [Abstract][Full Text] [Related]
6. Synergistic induction of lymphokine (IL-2)-activated killer activity by IL-2 and the polysaccharide lentinan, and therapy of spontaneous pulmonary metastases.
Yamasaki K; Sone S; Yamashita T; Ogura T
Cancer Immunol Immunother; 1989; 29(2):87-92. PubMed ID: 2785852
[TBL] [Abstract][Full Text] [Related]
7. Effect of host age upon interleukin-2-mediated anti-tumor responses in a murine fibrosarcoma model.
Ho SP; Kramer KE; Ershler WB
Cancer Immunol Immunother; 1990; 31(3):146-50. PubMed ID: 2337904
[TBL] [Abstract][Full Text] [Related]
8. The tumor-bearing state induces augmented responses of organ-associated lymphocytes to high-dose interleukin-2 therapy in mice.
Asano Y; Kaneda K; Hiragushi J; Tsuchida T; Higashino K
Cancer Immunol Immunother; 1997 Oct; 45(2):63-70. PubMed ID: 9390196
[TBL] [Abstract][Full Text] [Related]
9. Distinct biological activities of recombinant forms of human interleukin-2 in vivo.
Lentsch AB; Nakagawa K; Yoshidome H; Gerassimides A; Miller FN; Edwards MJ
Cancer Immunol Immunother; 1997 Jan; 43(6):331-6. PubMed ID: 9067404
[TBL] [Abstract][Full Text] [Related]
10. The role of interleukin-2 in cancer therapy.
Kohler PC; Sondel PM
Cancer Surv; 1989; 8(4):861-73. PubMed ID: 2701732
[TBL] [Abstract][Full Text] [Related]
11. Prolonged interleukin-2 (IL-2) treatment can augment immune activation without enhancing antitumor activity in renal cell carcinoma.
Sosman JA; Hank JA; Moore KH; Borchert A; Schell K; Kohler PC; Goldstein D; Bechhofer R; Storer B; Albertini MR
Cancer Invest; 1991; 9(1):35-48. PubMed ID: 2012995
[TBL] [Abstract][Full Text] [Related]
12. [Induction of lymphokine activated killer (LAK) and prolongation of its activity by intrasplenic injection of interleukin 2 (IL-2) in combination with tumor necrosis factor (TNF)].
Nakajima I; Okuno K; Ohnishi H; Shilayama Y; Nakamura T; Hirohata T; Yasutomi M
Nihon Geka Gakkai Zasshi; 1990 Oct; 91(10):1548-53. PubMed ID: 2263237
[TBL] [Abstract][Full Text] [Related]
13. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
[TBL] [Abstract][Full Text] [Related]
14. [Injection of interleukin-2 (IL-2) into the tumor-bearer's spleen augments lymphokine-activated killer (LAK) activity in vitro and inhibits tumor metastasis].
Okuno K; Ohnishi H; Takagi H; Nakamura T; Kokudo S; Yasutomi M
Nihon Geka Gakkai Zasshi; 1987 Jul; 88(7):802-7. PubMed ID: 3499562
[TBL] [Abstract][Full Text] [Related]
15. TNF-alpha potentiation of the lymphokine-activated killer response of murine thymus cells.
Ujházy P; Maccubbin D; Eppolito C; Mihich E; Ehrke MJ
Lymphokine Cytokine Res; 1994 Apr; 13(2):99-106. PubMed ID: 8061121
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
